European Union authorises Covid vaccine produced by Johnson & Johnson

EU has authorised the use of a Covid-19 vaccine produced by Johnson & Johnson, only hours after the EMA made a positive recommendation based on scientific assessment of its efficacy

Johnson
Vials of J&J vaccine
IANS Brussels
2 min read Last Updated : Mar 12 2021 | 10:13 AM IST

The European Union (EU) has authorised the use of a Covid-19 vaccine produced by Johnson & Johnson, only hours after the European Medicines Agency (EMA) made a positive recommendation based on scientific assessment of its efficacy and safety.

Developed by Janssen, the pharmaceutical arm of Johnson & Johnson, it is the fourth vaccine the EU has granted the conditional marketing authorisation, after the ones developed by BioNTech-Pfizer, Moderna and AstraZeneca, reports Xinhua news agency.

"More safe and effective vaccines are coming to the market," European Commission President Ursula von der Leyen tweeted on Thursday.

"With the number of doses we ordered, we could vaccinate up to 200 million people in the EU."

On Thursday afternoon, the EMA recommended the use of the Janssen vaccine among people over 18 years of age.

It is also the first Covid-19 vaccine which can be used in a single dose, said EMA's Executive Director Emer Cooke.

Results from a clinical trial involving 44,000 people in the US, South Africa and Latin American countries showed that the vaccine had a 67 per cent efficacy, according to the EMA.

The EU has rolled out vaccination programs aiming at inoculating 70 per cent of its adult population by September 21, 2021.

Meanwhile, 263 candidate vaccines are still being developed worldwide, 81 of them in clinical trials, according to the World Health Organization.

--IANS

ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :European UnionJohnson & JohnsonCoronavirus Vaccine

First Published: Mar 12 2021 | 10:05 AM IST

Next Story